Title : Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.

Pub. Date : 2021 Jun

PMID : 33455055






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Coadministration of lemborexant with bupropion resulted in 49.9% and 45.5% decreases in S-bupropion Cmax and AUC0-inf , respectively.Comparison of estimated exposures for patients in phase 3 trials who were/were not receiving concomitant weak CYP3A inhibitors substantiated the DDI pharmacokinetic findings. Bupropion cytochrome P450 family 3 subfamily A member 4 Homo sapiens